Agkistrodon piscivorus piscivorus platelet aggregation inhibitor: a potent inhibitor of platelet activation.
- 1 October 1989
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 86 (20) , 8050-8054
- https://doi.org/10.1073/pnas.86.20.8050
Abstract
Applaggin (Agkistrodon piscivorus piscivorus platelet aggregation inhibitor) is a potent inhibitor of platelet activation. The protein is isolated from the venom of the North American water moccasin snake in three steps, including gel filtration, cation exchange, and reverse-phase HPLC procedures. The purified protein migrates as a 17,700-Da polypeptide by SDS/PAGE under nonreducing conditions and as a 9800-Da peptide in the presence of thiol. The behavior of applaggin on SDS/PAGE would indicate that the protein is a disulflide-linked dimer. Applaggin has been completely sequenced by Edman degradation and consists of 71 amino acids. The sequence is rich in cysteine and contains Arg-Gly-Asp at residues 50-52. Applaggin blocks platelet aggregation induced by ADP, collagen, thrombin, or arachidonic acid with IC50 values ranging from 12 to 128 nM (0.2-2.3 .mu.g/ml) depending on the agonist and its concentration. This inhibition is found to correlate with inhibition of thromboxane A2 generation and of dense granule release of serotonin. Inhibition by applaggin of serotonin release induced by ADP, .gamma.-thrombin, and collagen was monitored in plasma under stirred conditions with [3H]serotonin-loaded platelets, and IC50 values for inhibition are found to range from < 10 to 145 nM. At saturating concentrations, 125I-labeled applaggin (125I-applaggin binds to 28,500 sites per unstimulated, washed platelet with a Kd of 1.22 .times. 10-7 M. Binding of 125I-applaggin to platelets is inhibited by the synthetic undecapeptide Arg8-Gly-Asp-Val at 200 .mu.M.This publication has 29 references indexed in Scilit:
- Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human plateletsBiochemistry, 1989
- Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.Journal of Clinical Investigation, 1988
- Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.Journal of Clinical Investigation, 1988
- The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets.Proceedings of the National Academy of Sciences, 1985
- Independent modulation of von Willebrand factor and fibrinogen binding to the platelet membrane glycoprotein IIb/IIIa complex as demonstrated by monoclonal antibody.Journal of Clinical Investigation, 1985
- Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the .gamma. chainBiochemistry, 1984
- Platelets have more than one binding site for von Willebrand factor.Journal of Clinical Investigation, 1983
- gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors.Proceedings of the National Academy of Sciences, 1982
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978
- Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranesNature, 1975